Nishida Takahiro, Sonoda Hiromichi, Oishi Yasuhisa, Tatewaki Hideki, Tanoue Yoshihisa, Shiokawa Yuichi, Tominaga Ryuji
Department of Cardiovascular Surgery, Kyushu University Graduate School of Medical Sciences.
Circ J. 2014;78(11):2688-95. doi: 10.1253/circj.cj-14-0466. Epub 2014 Sep 27.
The long-term results of aortic valve replacement (AVR; n=737) with bileaflet mechanical prosthesis (MP) or Carpentier-Edwards Perimount bioprostheses (BP) were evaluated in different age groups. METHODS AND RESULTS: Since 1981, a total of 737 prostheses (424 bileaflet MP vs. 313 BP) were implanted for AVR in 278 patients aged ≥70 years (79 MP vs. 199 BP), in 191 patients aged 60-69 years (128 MP vs. 63 BP) and in 268 patients aged <60 years (217 MP vs. 51 BP). Follow-up was completed for 6,523 patient-years in 98.5% of cases. Among the patients ≥70 years, both the actuarial survival rate (P=0.0434) and freedom from valve-related morbidity (P=0.0205) were better in the BP group than in the MP group without any difference in occurrence of structural valve deterioration in both groups. Among the patients aged 60-69, anticoagulant-related complications occurred less often in the BP group (P=0.0134) without any difference in long-term survival. Among the patients aged <60, long-term survival was significantly better in the MP group, whereas freedom from anticoagulant-related events did not differ.
The use of BP is suitable in patients aged ≥70 years, while the use of bileaflet MP is preferable in patients aged <60 years. Among patients aged 60-69 years, the use of BP is acceptable because of the lower incidence of anticoagulant-related events and the equivalent long-term survival.
在不同年龄组中评估了使用双叶机械瓣膜(MP)或卡彭蒂埃 - 爱德华兹Perimount生物瓣膜(BP)进行主动脉瓣置换术(AVR;n = 737)的长期结果。
自1981年以来,共为278例年龄≥70岁的患者(79例MP vs. 199例BP)、191例年龄60 - 69岁的患者(128例MP vs. 63例BP)和268例年龄<60岁的患者(217例MP vs. 51例BP)植入了737个瓣膜(424个双叶MP vs. 313个BP)用于AVR。98.5%的病例完成了6523患者年的随访。在≥70岁的患者中,BP组的精算生存率(P = 0.0434)和无瓣膜相关并发症发生率(P = 0.0205)均优于MP组,两组结构性瓣膜退变的发生率无差异。在60 - 69岁的患者中,BP组抗凝相关并发症的发生率较低(P = 0.0134),长期生存率无差异。在<60岁的患者中,MP组的长期生存率明显更好,而抗凝相关事件的发生率无差异。
对于年龄≥70岁的患者,使用BP是合适的;而对于年龄<60岁的患者,使用双叶MP更可取。在年龄60 - 69岁的患者中,由于抗凝相关事件的发生率较低且长期生存率相当,使用BP是可以接受的。